Shots:
- Novartis has reported that Cosentyx met all 1 & 2 EPs in the P-III trial in adults with PMR
- The global P-III (REPLENISH) trial showed that Cosentyx (secukinumab) significantly improved sustained remission at Wk 52 in PMR pts vs PBO, with a reduced steroid dose and a safety profile consistent with prior use. Conducted across 27 countries, the study tested Cosentyx 300mg or 150mg plus a 24-wk steroid taper. Results support Cosentyx as a potential new targeted treatment for PMR, a common inflammatory disease in adults 50+. Data will be presented at a future medical congress and submitted to regulators in H1’26
- Cosentyx is a fully human biologic that blocks interleukin-17A, a key driver of inflammation in various immune-mediated diseases
Ref: Novartis | Image: Novartis | Press Release
Related News:- Novartis Highlights P-III (APPLAUSE-IgAN) Trial Findings on Fabhalta (Iptacopan) for IgA Nephropathy
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
